Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

该方案于2020年3月获得IRB批准，但由于COVID-19大流行而无法开始招募。此后，该计划进行了修订，并于2020年8月开始招聘。自3月以来，为了确保征聘和科目应计与机构规范相结合，进行了少量修改，议定书也作了相应的修订。已经在实验室测试了处理血液样本的标准操作方案，并开发了血小板功能测定方法。在与检验医学部门的合作下，将对方案招募的所有受试者进行血栓弹性成像。该方案将招募两组受试者，两组受试者都将进行为期两年的前瞻性随访。一组SCD患者将进行现场随访，而另一组SCT和健康个体将通过远程医疗进行随访。

The protocol was approved by the IRB in March 2020 but could not begin recruitment due to the COVID-19 pandemic. Since then it has been amended and recruitment has begun in August 2020. Since March, minor modifications to ensure that recruitment and subject accrual are in conjunction with institutional norms have been implemented and the protocol has been amended accordingly. Standard operating protocols for processing of blood samples have been tested in the laboratory and assays for platelet function have been developed. In collaboration with the department of laboratory medicine, thromboelastography will be performed on all subjects recruited to the protocol. The protocol will enroll two cohorts of subjects, both of which will be followed prospectively for a period of two years. One cohort consisting of SCD patients will be followed up on site whereas the other cohort of SCT and healthy individuals will be followed up via Telehealth.